Melphalan-based chemo regimens for light-chain amyloidosis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1606, 2007-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Managing Systemic Light-Chain Amyloidosis

By Comenzo Raymond L.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 2, 2007-02 ,pp. : 179-187

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Lenalidomide/melphalan/prednisone: Light-chain deposition disease leading to ischaemic cholangitis in an elderly patient with multiple myeloma: case report

Reactions Weekly, Vol. 1, Iss. 1241, 2009-01 ,pp. : 29-30

Adis International

Access to resources Recommend Favorite

Amyloid Formation in Light Chain Amyloidosis

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 22, 2012-11 ,pp. : 2523-2533

Bentham Science Publishers

Access to resources Recommend Favorite

Two chemo regimens show similar benefit in breast cancer

Inpharma, Vol. 1, Iss. 1254, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Irinotecan-based chemo for paediatric rhabdomyosarcoma

Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite